Nonoperating Income (Expense) in USD of KnightSwan Acquisition Corp from Q3 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
KnightSwan Acquisition Corp quarterly and annual Nonoperating Income (Expense) history and change rate from Q3 2021 to Q3 2023.
  • KnightSwan Acquisition Corp Nonoperating Income (Expense) for the quarter ending 30 Sep 2023 was $1,363,130, a 28.1% increase year-over-year.
  • KnightSwan Acquisition Corp Nonoperating Income (Expense) for the twelve months ending 30 Sep 2023 was $8,763,895.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)

KnightSwan Acquisition Corp Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2023 $8,763,895 $1,363,130 +$299,064 +28% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $8,464,831 $2,869,239 +$2,549,571 +798% 01 Apr 2023 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 $5,915,260 $2,537,219 +$2,515,763 +11,725% 01 Jan 2023 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 $3,399,497 $1,994,307 01 Oct 2022 31 Dec 2022 10-K 24 Mar 2023 2022 Q4
Q3 2022 $1,064,066 +$1,064,066 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $319,668 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $21,456 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $0 13 Aug 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3

KnightSwan Acquisition Corp Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $3,399,497 01 Jan 2022 31 Dec 2022 10-K 24 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.